JP2022521605A5 - - Google Patents

Info

Publication number
JP2022521605A5
JP2022521605A5 JP2021549625A JP2021549625A JP2022521605A5 JP 2022521605 A5 JP2022521605 A5 JP 2022521605A5 JP 2021549625 A JP2021549625 A JP 2021549625A JP 2021549625 A JP2021549625 A JP 2021549625A JP 2022521605 A5 JP2022521605 A5 JP 2022521605A5
Authority
JP
Japan
Prior art keywords
compound
formula
alkyl
pharmaceutically acceptable
och
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021549625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521605A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019552 external-priority patent/WO2020176428A1/en
Publication of JP2022521605A publication Critical patent/JP2022521605A/ja
Publication of JP2022521605A5 publication Critical patent/JP2022521605A5/ja
Pending legal-status Critical Current

Links

JP2021549625A 2019-02-25 2020-02-24 統合的ストレス応答経路の阻害剤 Pending JP2022521605A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962810324P 2019-02-25 2019-02-25
US62/810,324 2019-02-25
US201962943643P 2019-12-04 2019-12-04
US62/943,643 2019-12-04
PCT/US2020/019552 WO2020176428A1 (en) 2019-02-25 2020-02-24 Inhibitors of integrated stress response pathway

Publications (2)

Publication Number Publication Date
JP2022521605A JP2022521605A (ja) 2022-04-11
JP2022521605A5 true JP2022521605A5 (cg-RX-API-DMAC10.html) 2023-03-06

Family

ID=72141533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549625A Pending JP2022521605A (ja) 2019-02-25 2020-02-24 統合的ストレス応答経路の阻害剤

Country Status (13)

Country Link
US (1) US20200270232A1 (cg-RX-API-DMAC10.html)
EP (1) EP3930697A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022521605A (cg-RX-API-DMAC10.html)
KR (1) KR20210134351A (cg-RX-API-DMAC10.html)
CN (1) CN113840597A (cg-RX-API-DMAC10.html)
AU (1) AU2020229748A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021014514A2 (cg-RX-API-DMAC10.html)
CA (1) CA3130511A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021002238A1 (cg-RX-API-DMAC10.html)
IL (1) IL285697A (cg-RX-API-DMAC10.html)
MX (1) MX2021010106A (cg-RX-API-DMAC10.html)
SG (1) SG11202107871UA (cg-RX-API-DMAC10.html)
WO (1) WO2020176428A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
US11166942B2 (en) 2018-06-05 2021-11-09 Praxis Biotech LLC Inhibitors of integrated stress response pathway
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
KR20220151635A (ko) 2020-03-11 2022-11-15 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
MX2023004677A (es) 2020-10-22 2023-05-24 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
ES2997335T3 (en) 2020-10-22 2025-02-17 Evotec Int Gmbh Modulators of the integrated stress response pathway
EP4001917A1 (en) 2020-11-12 2022-05-25 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Inhibitors for use in treating liver disorders
WO2023014431A1 (en) * 2021-08-02 2023-02-09 The Regents Of The University Of Colorado Bacterial efflux pump inhibitors and methods of use
KR102992203B1 (ko) * 2024-02-05 2026-07-20 재단법인 대구경북첨단의료산업진흥재단 신규한 eIF2B 작용제 및 이를 포함하는 대사질환 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197350A1 (en) * 2003-03-31 2005-09-08 Taisho Pharmaceutical Co., Ltd. Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
JP4868731B2 (ja) * 2004-11-17 2012-02-01 独立行政法人理化学研究所 哺乳動物培養細胞由来の無細胞タンパク質合成システム
WO2014072061A1 (en) * 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
WO2014144952A2 (en) * 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
TW201808903A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI920577B (zh) * 2016-05-05 2026-04-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808888A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
CA3026983A1 (en) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds

Similar Documents

Publication Publication Date Title
JP2021527044A5 (cg-RX-API-DMAC10.html)
JP2022536663A5 (cg-RX-API-DMAC10.html)
RU2020122711A (ru) Ингибиторы пути интегрированной реакции на стресс
JP2022536901A5 (cg-RX-API-DMAC10.html)
JP2020525512A (ja) 癌および他の疾患を処置するためのATF4阻害剤としての2−(4−クロロフェノキシ)−N−((1−(2−(4−クロロフェノキシ)エチンアゼチジン(ethynazetidin)−3−イル)メチル)アセトアミド誘導体および関連化合物
JP6739548B2 (ja) ベンザゼピン誘導体、その製造方法、薬物組成物および使用
JP2021529814A (ja) 化学化合物
US20200297710A1 (en) Chemical Compounds
JP2022536663A (ja) 統合的ストレス応答経路のモジュレーター
JP2024509962A (ja) 複素環及びその使用
WO2020031107A1 (en) Chemical compounds
US9963464B2 (en) Macrocyclic compounds
CN114174281A (zh) 细胞周期蛋白依赖性激酶7(cdk7)的降解剂及其用途
SG11202107871UA (en) Inhibitors of integrated stress response pathway
JP2022542669A (ja) Irak4キナーゼ阻害剤及びその調製方法
US20200101047A1 (en) Inhibitors of integrated stress response pathway
CA3255890A1 (en) Conjugate comprising toll-like receptor agonist
JP2010526867A5 (cg-RX-API-DMAC10.html)
JP7014914B2 (ja) 血管炎及び炎症性疾患を治療するためのc5a受容体調節剤としての2,4,6,7-テトラヒドロ-ピラゾロ[4,3-d]ピリミジン-5-オン誘導体及び関連化合物
CA3001085A1 (en) Novel modified macrocyclic compounds
AU2015274285C1 (en) Pyrimidine compounds and methods using the same
CA2999931A1 (en) Novel macrocyclic sulfondiimine compounds
JP7329052B2 (ja) フッ素含有置換ベンゾチオフェン化合物ならびにその医薬組成物および応用
RU2021128007A (ru) Ингибиторы пути интегрированной реакции на стресс
WO2013147216A1 (ja) (2-ヘテロアリールアミノ)コハク酸誘導体